BioCon net profit decreases by 95% yoy, operating Powering Revenue increases by 15%

BioCon reduced the finished-June expired net profit in the first quarter by 95%-year-by-year-year. However, the company has claimed that the sale of its branded formulations India (BFI) business of Iris Lifeicins of the business, oncology and critical care portfolio, has increased the one -year divasting gain in the same quarter, after a 65% profit.

Operating Powering Revenue for the company’s Q1FY26 increased by 15% annually to Rs. 3,942 crore, while EBITDA in the quarter was Rs. 829 crore, as the EBITDA margin was 21% margin on the basis of the same, the company said in a statement.

“Recent QIP has strengthened our balance sheet and enables us to enhance our ownership by setting up a capital structure with a long-term strategic priority,” said Kir Mazumdar-Show, chairman of Biocon Group, and the recent QIP has strengthened our balance sheet.

“We are in a good position to run long -term value construction of the financial year 26 and beyond the fiscal year 26 and beyond the capacity of all businesses with execution motion and extended capacity by Sinjen and Biocon Generics in the US.”

Biocon concluded its first equity fund after the 2004 IPO, with eligible organizations placement (QIP) in June. 4,500 crores were raised. The funds will be used to increase the holding of biocon in Biocon Biologics and exit private equity investors in Bicon Biologics, the company said.

The operation in the company’s API and generic formulations business has increased 697 crore revenue from 6%.

“The growth in the quarter was mainly run by the recent drug product launch revenue, including liraglutide in the EU, and Dasatinib and Lenalidomide in the US, supported by high volumes in our API business.”

“We focus on starting new products, including the commercialization of liraglutide in key strategic markets,” he added.

Biocon Biologics recorded a revenue growth annually, which is operated by strong demand in key markets.

With the operation, the company’s CRDMO Business Cijen’s revenue increased 11% annually to Rs. 875 crore and EBITDA is Rs 224 crore, which reports a growth of 19%.

“Research services were constantly growing at a pace, as pilot programs were infected with a long -term agreement,” said Peter Bens, CEO and managing director of Singh International.